The loss of ITK or its activity, either by mutation or through the use of inhibitors, has led to beneficial outcomes in experimental models of asthma, inflammatory bowel disease, and multiple sclerosis, among other diseases. The gene discussed is ITK; the disease is multiple sclerosis.